Provectus Biopharmaceuticals to Present at 18th Annual BIO CEO & Investor Conference
February 02 2016 - 6:00AM
Business Wire
Provectus Presentation Scheduled for 3:00 PM
EST on Monday February 8, 2016
Conference Runs February 8-9 2016 at
Waldorf-Astoria Hotel, New York, New York
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT,
www.pvct.com), a clinical-stage oncology and dermatology
biopharmaceutical company ("Provectus" or the "Company"), today
announced that it will present at the 18th Annual BIO CEO &
Investor Conference.
The Company’s presentation is currently scheduled for 3:00 pm
Eastern Standard Time on Monday, February 8, 2016. The presentation
is scheduled to take place in the Duke of Windsor room at the
Waldorf Astoria Hotel in New York, New York.
The presentation will be webcast live, which can be accessed via
http://www.veracast.com/webcasts/bio/ceoinvestor2016/23129153885.cfm.
In addition, replay will be available beginning one hour after the
presentation and will remain available through that same link
through May 8, 2016.
The presentation will also be available on the Provectus website
(www.pvct.com) upon conclusion of the live presentation at the
conference.
About the 18th Annual BIO CEO & Investor
Conference
The BIO CEO & Investor Conference is one of the largest
investor conferences focused on established and emerging publicly
traded and select private biotech companies. Because the BIO CEO
& Investor Conference mission is to support industry-wide
success, it presents a broad and unbiased view of investment
opportunities.
Each year the BIO CEO & Investor Conference provides a
neutral forum where institutional investors, industry analysts, and
senior biotechnology executives have the opportunity to shape the
future investment landscape of the biotechnology industry.
The conference features issue-oriented plenary sessions,
educational sessions focused on hot therapeutic areas and key
business issues, company presentations, one-on-one meetings, and
networking opportunities.
The conference’s therapeutic workshops feature MDs, CSOs and
industry analysts discussing the latest information on pipeline
innovation for breakthrough therapeutic topics in biopharma.
Seasoned industry executives and analysts delve into timely and
relevant business models, deal-making and investment trends on the
conference’s business roundtables.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing
oncology and dermatology therapies. PV-10, its novel
investigational drug for cancer, is designed for injection into
solid tumors (intralesional administration), thereby reducing
potential for systemic side effects. Its oncology focus is on
melanoma, breast cancer and cancers of the liver. The Company has
received orphan drug designations from the FDA for its melanoma and
hepatocellular carcinoma indications. PH-10, its topical
investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has
completed Phase 2 trials of PV-10 as a therapy for metastatic
melanoma, and of PH-10 as a topical treatment for atopic dermatitis
and psoriasis. Information about these and the Company's other
clinical trials can be found at the NIH
registry, www.clinicaltrials.gov. For additional information
about Provectus, please visit the Company's website at or contact
Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains
"forward-looking statements" as defined under U.S. federal
securities laws. These statements reflect management's current
knowledge, assumptions, beliefs, estimates, and expectations and
express management's current views of future performance, results,
and trends and may be identified by their use of terms such as
"anticipate," "believe," "could," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "will," and other similar
terms. Forward-looking statements are subject to a number of risks
and uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements.
Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this
date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking
statements include those discussed in our filings with the
Securities and Exchange Commission (including those described in
Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2014) and the following:
- our determination, based on guidance
from the FDA, whether to proceed with or without a partner with the
fully enrolled phase 3 trial of PV-10 to treat locally advanced
cutaneous melanoma and the costs associated with such a trial if it
is necessary to complete (versus interim data alone);
- our determination whether to license
PV-10, our investigational drug product for melanoma and other
solid tumors such as cancers of the liver, if such licensure is
appropriate considering the timing and structure of such a license,
or to commercialize PV-10 on our own to treat melanoma and other
solid tumors such as cancers of the liver;
- our ability to license PH-10, our
investigational drug product for dermatology, PH-10, on the basis
of our phase 2 atopic dermatitis and psoriasis results, which are
in the process of being further developed in conjunction with
mechanism of action studies; and
- our ability to raise additional capital
if we determine to commercialize PV-10 and/or PH-10 on our own,
although our expectation is to be acquired by a prospective
pharmaceutical or biotech concern prior to commercialization.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160202005367/en/
Provectus Biopharmaceuticals, Inc.Peter R. Culpepper, CFO,
COO866-594-5999 #30orPorter, LeVay & Rose, Inc.Marlon Nurse,
DM, SVP – Investor Relations212-564-4700orAllison + PartnersTodd
Aydelotte, Managing Director –Media Relations646-428-0644
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024